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Background: Reperfusion injury remains a significant problem after lung 
transplantation and is thought to be in part mediated by neutrophils. 
Ulinastatin inhibits release of elastase and cathepsin G from neutrophil 
granules. We hypothesized that inhibition of these neutrophil endopepti- 
dases (proteases) would attenuate pulmonary reperfusion injury. Methods: 
With an isolated, whole blood-perfused, ventilated rabbit lung model, we 
studied the effects of ulinastatin. All lungs were flushed with cold Euro- 
Collins solution, harvested en bloc, stored inflated at 4 ° C for 18 hours, and 
reperfused with whole blood. The 18-hour control ungs (n = 8) were stored 
and reperfused. Low-dose (n = 8) and high-dose (n = 7) groups were 
treated with total doses of ulinastatin of 25,000 and 50,000 units, respec- 
tively, during flush and reperfusion. An additional control group of lungs 
(n = 8) was harvested, flushed, and immediately reperfused. Results: The 
pulmonary artery pressure was significantly lower in the high-dose group 
than in the 18-hour control group (36.7 __ 1.8 vs 44.8 - 2 .9  mm Hg,  p = 
0.034). The percentage decrease in dynamic airway compliance was signif- 
icantly less in the high-dose group than in the 18-hour control group 
(-13.8% - 4.4% vs -25.1% --. 3.7%, p = 0.032). Both low-dose and 
high-dose ulinastatin treatments did not result in a significant improve- 
ment in oxygenation with respect o the 18-hour control group (72.2 - 25.8 
vs 32.5 --- 4.9 mm Hg, p = 0.21). Conclusions: Ulinastatin diminishes 
reperfusion injury after 18 hours of hypothermic pulmonary ischemia, with 
resultant improvements in pulmonary artery pressure and airway compli- 
ance. Improvement in pulmonary function after preservation and reperfu- 
sion with a neutrophil endopeptidase inhibitor confirms the role of 
endopeptidases in reperfusion injury and suggests an intervention to 
reduce their detrimental effects on early graft function. (J Thorac Cardio- 
vasc Surg 1996;112:607-13) 
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R eperfusion injury remains an important cause of 
Limpaired lung function after transplantation. 
This injury is believed to be partially mediated by 
the deleterious effects of neutrophils. The use of 
leukocyte-depleted blood during heart-lung trans- 
plantation has resulted in improvement in func- 
tional and histologic indexes. Successful lung trans- 
plantation after extended preservation with 
leukocyte-depleted blood has also been described. 2 
The concept of host responses contributing to 
pathologic processes is widely accepted. Tissue de- 
struction by neutrophils has been attributed to their 
ability to release "a complex assortment of agents 
that can destroy normal cells and dissolve connec- 
tive tissues. ''3 This process is initiated by pulmonary 
endothelial injury as a consequence of ischemia, 
poor preservation, and reperfusion of the lung. 
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During reperfusion, endothelial cells express inter- 
cellular adhesion molecules and endothelial leuko- 
cyte adhesion molecule, facilitating neutrophil ad- 
herence, activation, and subsequent toxin release. 4 
These neutrophil-generated toxins can be divided 
into two categories: reactive oxygen metabolites 
generated from the plasma membrane through the 
reduced nicotinamide adenine dinucleotide oxidase 
system and preformed endopeptidases (proteases) 
released from intracellular granules. 
Numerous investigations have demonstrated the 
role of reactive oxygen metabolites in reperfusion 
injury of pulmonary tissues after preservation s' 6; 
however, the role of neutrophil endopeptidases in 
reperfusion injury of the lung has yet to be eluci- 
dated. The aim of our study was to investigate the 
effect of these neutrophil endopeptidases on lung 
function after preservation and reperfusion. To ac- 
complish this, we used the neutrophil endopeptidase 
inhibitor ulinastatin (gift of Mochida Pharmaceuti- 
cal Co., LTD., Tokyo, Japan), which inhibits the 
actions of elastase and cathepsin G released from 
neutrophil granules. We hypothesized that inhibi- 
tion of these neutrophil endopeptidases would at- 
tenuate reperfusion injury and thus improve pulmo- 
nary function after 18 hours of cold ischemia. 
Materials and methods 
Lung-heart block harvesting. With the following exper- 
imental model previously described elsewhere, 7 31 adult 
New Zealand white rabbits of both sexes (3.0 to 3.5 kg) 
were randomly assigned to four experimental groups. 
Each rabbit was anesthetized with intramuscular ketamine 
(50 mg/kg) and xylazine (5 mg/kg). Tracheal intubation 
was performed through a tracheostomy and followed by 
paralysis with intravenous metocurine (0.2 mg/kg). Me- 
chanical ventilation was instituted (Ventilator RSP1002; 
Kent Scientific Corporation, Litchfield, Conn.) with room 
air at a tidal volume of 12 ml/kg and a rate of 20 
breaths/rain. 
A median sternotomy and a thymeetomy were then 
performed. The superior and inferior venae cavae were 
loosely encircled with ligatures and the pericardium was 
opened. Both the pulmonary artery (PA) and the aorta 
were dissected free and similarly encircled. A purse-string 
suture was then placed in the free wall of the right 
ventricle and intravenous heparin was administered (500 
U/kg). After injection of 30/~g prostaglandin E 1 (Alpros- 
tadil; Upjohn Company, Kalamazoo, Mich.) directly into 
the PA, the venae cavae were ligated to initiate the 
18-hour ischemic period. 
The PA was then cannulated through a right ventricu- 
lotomy in the center of the purse-string suture, and both 
the right ventricular and PA ligatures were tied around 
the cannula. After the left ventricle was vented through a 
left ventriculotomy and the aorta was ligated, 50 ml/kg 
Euro-Collins solution at 4°C was infused into the PA 
from a height of 30 cm. Topical cooling was achieved with 
cold saline solution slush. During PA flush, the left atrium 
(LA) was cannulated through the left ventriculotomy and 
a second purse-string suture was tied around the cannula. 
A second catheter was placed in the LA to directly 
transduce LA pressures. In the experimental groups des- 
ignated to receive ulinastatin, the endopeptidase inhibitor 
was administered with the final 15 ml flush solution and 
again at the onset of reperfusion. After the PA flush, the 
inflow and outflow cannulas were clamped. Care was 
taken to leave the pleurae intact until completion of the 
flush, to avoid parenchymal injury. The lungs were stored 
inflated by clamping of the tracheal tube at end-inspira- 
tion. The lung-heart block was then excised, immersed in 
cold 0.9% saline solution, and stored at 4 ° C for 18 hours. 
All experimental protocols were reviewed and approved 
by an institutional animal use committee. All animals 
received humane care in compliance with the "Guide for 
the Care and Use of Laboratory Animals" prepared by the 
Institute of Laboratory Animal Resources and published 
by the National Institutes of Health (NIH publication No. 
85-23, revised 1985). 
Assessment of lung function. After 18 hours of storage 
at 4 ° C, the lung-heart block was suspended by a force 
transducer in a warm, humidified tissue chamber. Venti- 
lation was reestablished with a 95% oxygen 5% carbon 
dioxide gas mixture at a tidal volume of 12 ml/kg and a 
respiratory rate of 20 breaths/rain. The lungs were reper- 
fused with homologous fresh whole venous blood from a 
main reservoir. A second venous blood reservoir was used 
to determine single-pass oxygenation values at 10, 20, and 
30 minutes after initiation of reperfusion. Blood was 
harvested from a single rabbit for each experiment. The 
inflow and outflow cannulas were then connected to the 
blood-primed perfusion circuit, with care taken to avoid 
introduction of air. The perfusion circuit (Kent Scientific 
Corporation) was designed to recirculate 150 ml warmed 
blood through a 270 /,m blood filter (2C7600; Baxter 
Healthcare Corp., Deerfield, Ill.) with a roller pump 
(7521-40; Cole-Parmer Instrument Company, Niles, Ill.) 
at a rate of 60 ml/min (Fig. 1). A 270 p~m blood filter was 
chosen to avoid affecting leukocyte and platelet counts. 
Continuous recordings of PA pressure (PAP), LA pres- 
sure, lung weight, airway flow, and airway pressure were 
facilitated by a dynamic data-acquisition program (Work- 
bench PC; Strawberry Tree, Inc., Sunnydale, Calif.) run 
on a personal computer (470A; Compaq Prolinea, Hous- 
ton, Texas). This program automatically calculated and 
displayed pulmonary vascular resistance (PVR), tidal vol- 
ume, and dynamic airway compliance. LA pressure was 
maintained within the physiologic range (4 to 8 mm Hg) 
by adjusting the height of a small outflow reservoir in the 
circuit. Pulmonary venous blood samples were collected 
for blood gas analysis (Corning 178 pH/Blood Gas Anal- 
yser; Coming Inc., Corning, N.Y.) at 10, 20, and 30 
minutes after the start of reperfusion. At each sampling 
interval, inflow from the main reservoir was interrupted 
and the circuit was filled with venous blood from the 
second inflow reservoir. A 30 ml sample of venous blood 
was passed through the pulmonary vasculature at each 
interval to ensure accurate measurement of pulmonary 
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Fig. 1. Schematic diagram of the model. P, Pressure transducer. 
venous oxygen content. Oxygen contact with exposed 
blood surfaces inside the reservoir containers was mini- 
mized by continuous infusion of 100% nitrogen. After 30 
minutes of reperfusion, specimens of lung tissue were 
acquired for weight analysis. Wet-to-dry ratios were cal- 
culated after passive desiccation at room temperature to a 
stable dry weight. 
Experimental protocol. All lungs were flushed with 
Euro-Collins olution and reperfused at a physiologic flow 
rate of 60 ml/min for 30 minutes. Four experimental 
groups were defined as follows: 18-hour control group 
lungs (n = 8) were reperfused without intervention after 
18 hours of storage, low-dose group lungs (n = 8) received 
2500 units ulinastatin during flush and 22,500 units at 
reperfusion, and high-dose group lungs (n = 7) received 
5000 units ulinastatin during flush and 45,000 units at 
reperfusion. The dosage of ulinastatin was determined 
according to the manufacturer's ecommendations for its 
use in clinical human shock states. An additional imme- 
diate control group (n = 8) underwent reperfusion imme- 
diately after flushing. Data were recorded every 15 sec- 
onds and analyzed at the end of the 30-minute reperfusion 
period. Oxygenation data were obtained and analyzed at 
10-minute intervals. All values are expressed as means (_+ 
standard error of the mean). Statistical analysis was 
performed by analysis of variance to compare the exper- 
imental groups. A difference was considered statistically 
significant if the p value was less than 0.05. 
Results 
All lungs demonstrated evidence of reperfusion 
injury when compared with the immediate control 
group. These changes were manifested as significant 
increases in PAP, PVR, and wet-to-dry ratios, in 
addition to significant decreases in airway compli- 
ance and oxygenation capacity. In our model, we 
defined oxygenation capacity as the ability of the 
lungs to oxygenate venous blood during a single pass 
from the PA to the LA. This was reported as a 
venous-arterial gradient (V-Ao2) to normalize for 
gradual decreases in the venous blood oxygen ten- 
sion during the course of the experiment. After 30 
minutes of reperfusion, the mean PAP of the high- 
dose group was significantly lower than that of the 
18-hour control group (36.7 _+ 1.8 vs 44.8 _+ 2.9 mm 
Hg, p = 0.034). There was no significant difference 
between the PAP of the high-dose group and that of 
the immediate control group (Fig. 2). Although the 
mean PVR was lower in the high-dose group, this 
difference was not significant compared with the 
18-hour control group (43,310 + 2044 vs 51,935 + 
4867 dynes • sec • cm -5, p = 0.41). The high-dose 
group also exhibited less of a drop in compliance 
than did the 18-hour control group ( -13.8% _+ 
4.4% vs -25.1% _+ 3.7%, p = 0.032; Fig. 3). The 
18-hour control lungs demonstrated significantly 
greater edema formation than did the immediate 
control group, as determined by higher wet-to-dry 
ratios (7.44 + 0.31 vs 5.50 + 0.25, p = 0.0014). 
Edema formation, as reflected by wet-to-dry ratios, 
was not significantly different between the high-dose 
and 18-hour control groups (6.58 _+ 0.29 vs 7.44 _+ 
0.31, p = 0.35; Fig. 4). The high-dose group dem- 
onstrated a higher mean V-Ao 2 gradient than did 
the 18-hour control group, although this difference 
610 Binns et al. 
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Fig. 2. Differences inPAP after 30 minutes of reperfusion. High-dose ulinastatin group (UL HD) exhibits 
decreased PAP compared with the 18-hour control group (18 con). UL LD, Low-dose ulinastatin group. 
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Fig. 3. Changes in lung compliance (CPL) after 30 minutes of reperfusion. High-dose ulinastatin group 
(UL HD) exhibits less drop in compliance than seen in the 18-hour control group (18 Con). UL LD, 
Low-dose ulinastatin group; Imm Con, immediate control group. 
failed to reach statistical significance (72.2 _+ 25.8 vs 
32.5 _+ 4.9 mm Hg, p = 0.21; Fig. 5). All of the lungs 
preserved for 18 hours demonstrated markedly de- 
creased oxygenation capacity (V-Ao2 gradient) com- 
pared with the immediate control lungs, which had a 
mean V-Ao 2 gradient of 361.3 _ 32.2 mm Hg. The 
low-dose group showed no improvements in PVR, 
dynamic compliance, wet-to-dry ratios, or V-Ao2 
compared with the 18-hour control group (V-Ao2, 
46.9 _+ 6.0 vs 32.5 _+ 4.9 mm Hg, p = 0.62). 
Discussion 
Reperfusion i jury after lung transplantation con- 
tinues to contribute to increased morbidity and 
mortality. Neutrophils are implicated as mediators 
of this reperfusion injury in the lung and other 
organs.l-3, s-ll Numerous investigators have demon- 
strated improved pulmonary function after ischemia 
by employing interventions to modulate neutrophil 
activity. These include the use of leukocyte-depleted 
blood, 8 antibodies directed at adhesion molecules 
expressed on the endothelial surface, 12 antibodies 
directed at the leukocyte integrin CD18,13 agents 
aimed at preventing the expression of integrin het- 
erodimers on the leukocyte surfac@ 4 and oxygen- 
free radical scavengers, s Morphologic hanges een 
in lung reperfusion i jury are consistent with dam- 
age caused by neutrophil endopeptidases 15 because 
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Fig. 4. Wet-to-dry ratios. Evidence of reperfusion i jury when comparing 18-hour control group (18 Con) 
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Fig. 5. V-Ao 2. NS, Not significant; 18 Con, 18-hour control group; Pao2, arterial oxygen tension. 
these proteins are able to destroy the extracellular 
matrix. Few studies, however, have investigated the 
specific role of neutrophil endopeptidases in reper- 
fusion injury of the lung. 16 
Under normal physiologic onditions, the action 
of these preformed enzymes is largely regulated by 
three antiendopeptidases: oq-proteinase inhibitor, 
o~2-macroglobulin, a d secretory leukoproteinase in-
hibitor. Evidence exists that chlorinated oxidants 
generated by neutrophils are able to "destroy the 
antiproteinase shield allowing unregulated proteo- 
lytic enzymes to attack and degrade host tissues. ''3 
Moreover, it is likely that periods of cold ischemia 
would attenuate synthesis of these antiendopepti- 
dases in preserved tissues, rendering them more 
susceptible to the uninhibited action of these en- 
dopeptidases. 
To investigate the effects of these endopeptidases 
on pulmonary reperfusion injury, we employed the 
inhibitor ulinastatin. This glycoprotein solated from 
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human urine has been described as an inhibitory 
biologic response modifier. 17 Ulinastatin directly 
inhibits the actions of elastase and cathepsin G. It 
also indirectly inhibits the release of neutrophil 
endopeptidases by stabilizing lysosomal membranes. 
Ulinastatin has been employed in other organ mod- 
els of ischemia-reperfusion njury, 18-2° as well as in 
previous models of pulmonary injury. < 21 Horiguchi 
and Harada 16 demonstrated decreased PVR and 
leukocyte infiltration in their model of pulmonary 
ischemia nd reperfusion byusing ulinastatin; how- 
ever, no measurements of airway dynamics or oxy- 
genation capacity, both of which are important 
indexes in the study of lung function, were included. 
With an isolated, ventilated, perfused ex vivo 
rabbit lung model, we demonstrated evidence of 
reperfusion injury in all lungs preserved for 18 
hours. This injury was manifested by increases in 
PAP, PVR, and wet-to-dry ratios, accompanied by 
decreases in compliance and V-A%. Improvements 
in PAP and lung compliance by treatment with 
ulinastatin suggest enhanced preservation of the 
microcirculation's integrity and endothelial func- 
tion. Despite improvements of these parameters in
the high-dose group, a statistically significant im- 
provement in oxygenation with respect o 18-hour 
control group was not demonstrated. The ability of 
lungs to oxygenate the p rfusate remains the single 
most important parameter of lung function. De- 
creased oxygenation remains a sensitive marker of 
reperfusion i jury, and our esults uggest that other 
mechanisms of injury continue to be involved. The 
high-dose group did, however, show incremental 
improvement with time, whereas the 18-hour con- 
trol group demonstrated decreasing oxygenation as 
the reperfusion period progressed. This observation 
suggests ongoing neutrophil endopeptidase activity 
and worsening injury in the absence of the endopep- 
tidase inhibitor. It also corroborates previous find- 
ings of continued leukocyte-mediated injury minutes 
to hours after the onset of reperfusion. 
Similarly, improving oxygenation capacity with 
time in the low-dose group suggests activity of the 
endopeptidase inhibitor. The low-dose group failed, 
however, to show improvements in other parameters 
of lung function after 18 hours of cold ischemia. 
This most likely represents an inadequate dosage of 
ulinastatin in the face of such severe reperfusion 
injury. 
Lung transplantation remains a successful option 
for patients with end-stage lung disease, yet reper- 
fusion injury and resultant primary graft dysfunction 
continue to limit long-term lung preservation. As 
the need for organ replacement continues to out- 
pace options for organ procurement, we will be 
investigating methods of using organs previously 
thought unsuitable for transplantation. Along with 
the use of such organs, donation from persons 
without beating hearts, a model of injury considered 
to be more severe than that seen in conventional 
donors, may be employed with increasing frequen- 
cy. 2a As such changes take place in our organ 
procurement protocols, we may witness an even 
greater rate of reperfusion injury. This potential 
source of morbidity and mortality further empha- 
sizes the importance of the pathophysiology in- 
volved in this response and underscores the need for 
interventions designed to prevent or attenuate its 
deleterious effects. 
In conclusion, improvement in pulmonary func- 
tion after preservation and reperfusion with a 
neutrophil endopeptidase inhibitor confirms the 
role of endopeptidases in lung reperfusion injury. 
Further studies in large-animal transplant models 
are warranted to determine the potential efficacy 
of ulinastatin in ameliorating pulmonary isch- 
emia-reperfusion injury and to enhance our 
knowledge of the detrimental effects of neutrophil 
endopeptidases on early pulmonary graft func- 
tion. 
We thank Anthony J. Herring for his technical advice, 
Masayuki Hotokezaka, nd the Mochida Pharmaceutical 
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